



Sensorion Receives French Tech Pass Certification

Certification Recognizes Sensorion's Innovative Technology and Global Potential



Montpellier, February 11, 2016 (FR0012596468 – ALSEN) – Sensorion, a biotech company specializing in the treatment of inner ear diseases, today announced that it has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential.

The French Tech is a French initiative created in 2013 which incorporates metropolitan hubs known for their innovative start-ups. It aims to identify 200 to 300 small and medium enterprises (SME) throughout France with substantial development potential, in order to help them accelerate their growth and support their international expansion by providing them with a service offer and access to numerous networks of experts.

French Tech Pass certification provides promising companies preferential access to the financial, networking, and coaching services provided by Bpifrance, Business France, DGE (*Direction Générale des Entreprises*, or Directorate-General for Enterprise), Coface and Inpi and to the French Tech Pass regional partners and French Tech community networks.

For its third wave of certifications, the *Montpellier Méditerranée Métropole* French Tech mission panel chose, for the first time, start-ups from outside the digital sector. Sensorion has been granted this certification in recognition of its dynamic development, scientific and clinical breakthroughs, and technological potential to provide solutions to the particularly debilitating pathologies of the inner ear, a market estimated to be worth over \$10 billion worldwide¹.

Laurent Nguyen, CEO of Sensorion, comments: *“We are delighted to have received French Tech Pass certification. This recognition further validates the company’s unique expertise and demonstrates the belief in our ability to become a leading SME in the field of inner ear pathologies which can lead to highly-debilitating vertigo, hearing loss and tinnitus. This certification will enable us to gain access to an ecosystem of private and public entities committed to the values of innovation and have the ability to support our development.”*

...

About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop three drug candidate programs for treating the symptoms of vertigo and tinnitus, for preventing complications

¹ Source: Alcimed, Sensorion

associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion has a portfolio of 7 patent families, employs 16 staff and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative. Sensorion is listed on Alternext Paris since April 2015. www.sensorion-pharma.com

Contacts

Sensorion

Laurent Nguyen

CEO

contact@sensorion-pharma.com

Tel: +33 (0)4 67 20 77 30

Name: **SENSORION**

ISIN code: **FR0012596468**

Ticker: **ALSEN**

International Investor Relations

NewCap

Dusan Oresansky / Emmanuel Huynh

sensorion@newcap.eu

Tel: +33 (0)1 44 71 94 92

US Investor Relations

The Ruth Group

David Burke

dburke@theruthgroup.com

Tel: +1 (646) 536 7009



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 15-114 on March 27, 2015 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.